---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210283"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:04:28.150440+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma reports Q1 net loss of $48.4M; PREVAIL interim analysis planned for 4Q26

## Summary
- Net loss $48.4M for Q1 2026, compared to net loss $39.5M in Q1 2025.
- Cash and marketable securities $707.3M at March 31, down from $728.9M at Dec 31, 2025.
- Regulatory decisions on obicetrapib from EMA, UK, Switzerland expected in 2H26; potential launches by Menarini in 4Q26 in Germany and UK.
- PREVAIL CVOT interim analysis planned for 4Q2026, result expected 1Q2027; trial may stop for efficacy or complete by end of 2027.
- Completed enrollment in REMBRANDT Phase 3 (323 patients); RUBENS Phase 3 topline data expected by year-end 2026.

## SEC filing metadata
- accession: 0001193125-26-210283
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/0001193125-26-210283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/nams-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210283
- JSON: https://secwatch.observer/filing/0001193125-26-210283.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210283.txt

## Source-grounded claims
- claim_id: 7b5c44e5c188f51fb6aa5c706094c550e5b9345b
  claim: NewAmsterdam Pharma Co N.V. reported financial results for the quarter ended March 31, 2026.
  evidence_excerpt: On May 7, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/0001193125-26-210283-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.